Drug Testing
and Analysis
Research Article
Received: 15 April 2009
Revised: 20 September 2009
Accepted: 13 December 2009
Published online in Wiley Interscience: 9 February 2010
(www.drugtestinganalysis.com) DOI 10.1002/dta.112
An improved validated ultra high pressure
liquid chromatography method for separation
of tacrolimus impurities and its tautomers
Acharya Subasranjan,a,b∗ Srinivasulu Ca and Raoutray Hemantb
A selective, specific and sensitive ultra high pressure liquid chromatography (UHPLC) method was developed for determination
of tacrolimus degradation products and tautomers in the preparation of pharmaceuticals. The chromatographic separation
was performed on Waters ACQUITY UPLC system and BEH C8 column using gradient elution of mobile phase A (90 : 10 v/v of
0.1% v/v triflouroacetic acid solution and Acetonitrile) and mobile phase B (90 : 10 v/v acetonitrile and water) at a flow rate of
0.6 mL min−1 . Ultraviolet detection was performed at 210 nm. Tacrolimus, tautomers and impurities were chromatographed
with a total run time of 25 min. Calibration showed that the response of impurity was a linear function of concentration over the
range 0.3–6 µg mL−1 (r2 ≥ 0.999) and the method was validated over this range for precision, intermediate precision, accuracy,
linearity and specificity. For precision study, percentage relative standard deviation of each impurity was <15% (n = 6). The
method was found to be precise, accurate, linear and specific. The proposed method was successfully employed for estimation
c 2010 John Wiley & Sons, Ltd.
of tacrolimus impurities in pharmaceutical preparations. Copyright
Keywords: UHPLC; tacrolimus; tautomers; impurities; method validation
Introduction
Drug Test. Analysis 2010, 2, 107–112
∗
Correspondenceto:Acharya Subasranjan,DrReddy’sLaboratoriesLtd,Generics
AR&D, Innovation Plaza, Survey Nos. 42, 45, 46 & 54, Bachupalli,Qutubllapur,
RR dist-500072, AP, India. E-mail: subasranjana@drreddys.com
a Dr Reddy’s Laboratories Ltd, Generics AR&D, Innovation Plaza, Survey Nos. 42,
45, 46 & 54, Bachupalli,Qutubllapur, RR dist-500072, AP, India
b Ravenshaw College, Cuttack 753003, Orissa, India
c 2010 John Wiley & Sons, Ltd.
Copyright
107
Tacrolimus (TAC) is an active pharmaceutical ingredient with useful
immunosuppressive and antimicrobial activity. TAC, also known as
FK-506, has the chemical tricyclic structure, as shown in Figure 1.[1]
TAC epimerizes to an intermediate tautomer-I (Cis), which is
converted into tautomer-II (Trans) to reach equilibrium with three
forms, as shown in Figure 1.[2] The immunosuppressive activity
was found to be associated with the Cis-Trans conversion through
binding to FK506 binding protein.[3] TAC is very sensitive to
temperature and will degrade to form impurities with very closely
related structures by rearrangement, as shown in Figure 2.[2,4]
Separation of TAC, tautomers and its impurities is a major
challenge due to structural similarity as shown in Figure 2 and low
absorptivity at conventionally used detection wavelengths. TAC
exhibits a maximum absorbance at about 205 nm, which poses
difficulties in its estimation using ultraviolet spectroscopy.[5,6]
Many analytical approaches, such as liquid chromatography in combination with mass spectrometry,[7 – 18] fluorescence
detection,[19 – 20] ultraviolet detection[2,21] and HPTLC method[6]
are reported for determination of TAC in biological matrices, bulk
drugs, and formulations having limit of quantification (LOQ) ranging from µg/mg to pc/mg. Moreover all the above-mentioned
methods are orientated to the determination of the active pharmaceutical compound. Now-a-days, the pharmaceutical industry
is forced to assess strict control of impurities when manufacturing
drug substance and drug products.[22,23] Determination of impurities during the development of separation methods is one of
the main and difficult tasks for pharmaceutical analysts, especially
if determination of more and more impurities of closely related
structures is required. Reports on the determination of TAC-related
substances are rather limited. Related substance method (impurities) of TAC capsules appeared in The United States Pharmacopoeia
(USP) forum, which is based on normal phase chromatography
at 225 nm.[24] The published TAC impurity method demonstrates
analysis of two known impurities and one specified unknown
impurity with detection wavelength at 225 nm, whereas TAC exhibits maximum absorbance at 205 nm. The published method
also demonstrates use of multiple columns for separation of impurities with a total separation time of more than 45 min. By
considering all the above factors, a simple and sensitive method
should be developed to monitor all impurities of TAC.
In liquid chromatography, the analysis time can be reduced
by using small columns packed with sub-2 µm particles. In
addition, with sub-2 µm particles, due to the higher efficiency
and smaller retention volume, sensitivity is also improved. UHPLC,
which uses 1.7 µm particles at a maximum operating pressure of
1000 bar, has proved to be a suitable analytical technique with
the advantages of increased linear velocity (speed) and reduced
solvent consumption. Although UHPLC has been shown to achieve
high resolution in a relatively short time, there are few reports of
its application to the analysis of pharmaceutical products and their
impurities as an alternative to conventional HPLC analysis.
In order to improve the sensitivity and selectivity of the
chromatographic determination of TAC impurities, a simple
reversed-phase UHPLC method with UV detection at 210 nm, have
been developed, where all four impurities as well as tautomers
have been separated in a single analytical column with a run time of
25 min. In our study, Waters ACQUITY UPLC was successfully used
Drug Testing
and Analysis
A. Subasranjan, C. Srinivasulu and R. Hemant
Figure 1. Chemical structure of Tacrolimus & Tautomers.
Figure 2. Chemical structure of Tacrolimus Impurities.
for the quantitative estimation of immunomycin (process impurity
as Impurity-A), propyl analogue (process impurity as Impurity-B),
delta lactone (degradation product as Impurity-C) and regioisomer
(thermal degradation product as Impurity-D) by separating from
tautomer I and II. A reduction in separation time was achieved,
without compromising separation quality compared to other
traditional liquid chromatography (LC) methods.
Water was purified by a Millipore (Bedford, MA, USA) Milli-Q waterpurification system and passed through a 0.22 µm membrane
filter (Durapore; Millipore, Dublin, Ireland) before use.
Standard and test samples were prepared in HPLC grade
acetonitrile as diluent.
Equipment
Experimental
Chemicals and reagents
108
TAC, Impurity-A, Impurity-B and Impurity-C were purchased from
Biocon Ltd (Bangalore, India). Impurity-D was isolated at Dr.
Reddy’s Laboratories Ltd (Hyderabad, India). Acetonitrile (HPLCgrade) was purchased from J.T. Baker (Phillipsburg, New Jersey,
USA), and trifluoroacetic acid, sodium hydroxide, hydrochloric
acid, hydrogen peroxide were from Merck (Darmstadt, Germany).
www.drugtestinganalysis.com
UHPLC analysis was performed with a Waters (Milford, MA,
USA) Acquity UPLC system equipped with a quaternary solvent
manager, sample manager, column-heating compartment, and
photodiode array detector. This system was controlled by Waters
Empower software.
An ACQUITY UPLC BEH C8 column, 100 mm × 2.1 mm,
1.7 µm (Waters (Milford, MA, USA) employed for chromatographic
separation. All samples were centrifuged by Thermo Scientific
multifuged machine. The specificity study was conducted by
c 2010 John Wiley & Sons, Ltd.
Copyright
Drug Test. Analysis 2010, 2, 107–112
Drug Testing
and Analysis
An improved validated ultra high pressure liquid chromatography method
using heating oven, photo stability chamber and heating mantle
(Thermo Lab, Thane, India).
Standard and sample preparation
The impurity stock solution was prepared by dissolving an
accurately weighed amount of Impurity-A and Impurity-D in
acetonitrile, resulting in a concentration of 30 µg mL−1 of each
impurity.
The identification solution was prepared by dissolving 6 mg of
TAC in 5 mL of diluent, mixed with 1 mL of impurity stock solution
and diluted to 10 mL in diluent.
The standard stock solution of TAC was prepared by dissolving
an accurately weighed amount of TAC working standard in diluent,
resulting in a concentration of 0.6 mg/mL. Then the solution was
further diluted in diluent to get a final solution of 3 µg mL−1 .
The test solution was prepared by dissolving an accurately
weighed portion of the powder, equivalent to 6 mg of TAC in 5 mL
diluent. After sonicating for around 5 min, the volume was made
up to 10 ml. The solution was centrifuged at 3000 rpm for 5 min
in order to eliminate insoluble excipients. The supernatant liquid
was used for chromatographic analysis.
Chromatography
The analytes were separated on an Acquity UPLC C8 column
(100 mm × 2.1 id, 1.7 µm) at oven temperature of 50 ◦ C with
a gradient run program at a flow-rate of 0.6 mL min−1 . The
separation was achieved by gradient elution and the beginning
ratio of mobile phase was A–B 55 : 45 (V/V); then the ratio was
changed linearly 45 : 55 (V/V); within 20 min. The system came
back to initial ratio at 21 min and continued at the same ratio for
4 min. The mobile phase was filtered through a 0.22 µm Millipore
filter, before use. UV detection was performed at 210 nm. The
sample injection volume was 5 µL in partial-loop mode.
Precision
The precision of test method was evaluated by using six samples
of TAC capsules test preparation, spiking with impurities blend
solution to get the concentration of 3 µg mL−1 of each impurity
and analyzed as per test method. Intermediate precision was
also studied using different column and performing analysis on a
different day.
Accuracy
To confirm the accuracy of the proposed method, recovery studies
were carried out by standard addition technique. Samples were
prepared in triplicate by spiking impurities in test preparation
at the level of LOQ, 50%, 100%, 150% and 200% (a nominal
concentration of about 0.3 µg mL−1 to 6 µg mL−1 ) of the standard
concentration.
Sensitivity
Sensitivity of the method was established with respect to limit
of detection (LOD) and LOQ for TAC impurities (i.e., Impurity-A,
Impurity-B, Impurity-C and Impurity-D). A series of concentration
of drug solution and its impurities were injected; LOD and LOQ
were established by slope method as mentioned below.
3.3 × standard deviation of y-intercept
Slope of the calibration curve
10 × standard deviation of y-intercept
LOQ =
Slope of the Ccalibration curve
LOQ =
Method validation
The method was validated for specificity, precision, accuracy,
sensitivity and linear range as per the International Conference on
Harmonization (ICH) guidelines.[26]
LOD and LOQ were experimentally verified by injecting six
replicate injections of each impurity at the concentration obtained
from the above formula.
Specificity
Linearity of detector response
A series of solutions of TAC impurities in the concentration ranging
from LOQ level (0.3 µg mL−1 ) to 200% (6 µg mL−1 ) of standard
concentration were prepared and injected into the UHPLC system.
Application of developed method
The method suitability was verified by analyzing three different
strengths of finished product of both innovator and in-house
formulated product. The content of 25 capsules (each containing
5 mg/1mg/0.5 mg of TAC) were emptied and intimately mixed.
Quantity equivalent to 6 mg of drug weighed accurately and
dissolved in 10 mL of acetonitrile by 5 min of sonication. The
solution was centrifuged and injected.
c 2010 John Wiley & Sons, Ltd.
Copyright
www.drugtestinganalysis.com
109
A study was conducted to demonstrate the effective separation
of TAC, tautomers and its impurities. The study was intended
to ensure the effective separation of degradation peaks of
formulation ingredients at the retention time of TAC, tautomers
and its impurities. Separate portions of drug product and
ingredients were exposed to the following stress conditions to
induce degradation.
The drug product was subjected to base hydrolysis using 1
N sodium hydroxide, acid hydrolysis with 1N hydrochloric acid
and neutral hydrolysis with water at 60 ◦ C for a duration of
12h. Oxidation study was performed with 1% hydrogen peroxide
solution at 60 ◦ C for 12 h. On photo stability study, drug product
was sufficiently spread on petri plates (1 mm thick layer), exposed
to sunlight and UV light (1.2 million lux hours) at ambient
conditions for 7 days. Humidity study was performed separately
by exposing the drug product to humidity at 25 ◦ C, 90% RH for
7 days. Thermal degradation study was performed by heating
drug product at 60 ◦ C for 48 h. Similarly, placebo samples were
Drug Test. Analysis 2010, 2, 107–112
prepared like a drug product by exposing formulation matrices
without drug substance.
Stressed samples were injected into the UHPLC system with
photo diode array detector by the following test method
conditions.
Drug Testing
and Analysis
A. Subasranjan, C. Srinivasulu and R. Hemant
Results and Discussion
A reversed-phase chromatographic technique was developed to
quantitate TAC and its impurities at 210 nm. The presence of
non-aqueous solvents in the mobile phase, such as methanol and
acetonitrile, was studied. Since the sensitivity of the detection
system was strongly reduced in the presence of methanol,
acetonitrile was chosen as an organic modifier. Satisfactory
separation was achieved when the acetonitrile concentration was
10% in mobile phase A and 90% in mobile phase B.
The effect of TFA concentration on analyte retention was
studied. TFA is known to improve peak shape and resolution
by reducing the analyte interaction with residual silanol groups at
the chromatographic surface. TFA is expected to reduce the virtual
polarity of the analyte in acidic media. Consequently the retention
of the compound increases when the eluent contains TFA. At low
pH and high operating column temperature, hydrolysis of the
siloxane bond can occur, stripping the bonded phase from the
silica support. To avoid this, 10 part of 0.1% v/v TFA solution used
in mobile phase A only. Satisfactory resolution was achieved with
use of a mixture of water, TFA and acetonitrile as demonstrated in
Figure 3C.
C8 and C18 columns were first evaluated as stationary phase for
the separation of TAC and its impurities. C8 column was adopted for
the analysis because it provided a better separation of the analytes,
whereas all analytes were retained so thoroughly that they were
not observed 25 min after injection in C18 column. Sensitivity of
the method is also improved, compared to conventional HPLC
method by reducing the particle size of the stationary phase and
detection at 210 nm, where TAC exhibits maximum absorbance.
Selectivity, sensitivity, resolution, and speed of chromatographic
separation were optimized for the UHPLC method. The optimized
UHPLC procedure was compared with previously published HPLC
method.[24] Comparing the signal to noise ratio of TAC standard
preparation, it is confirmed that proposed method has better
sensitivity. Present UHPLC method offers well resolution within
25 min. The retention times of TAC at 15.5, Tautomer-I at 9.3,
Tautomer-II at 13.7, Impurity-A at 14.5, Impurity-B at 18.6, ImpurityC at 17.3 and Impurity-D at 12.9 min respectively, under the
chromatographic conditions described. Chromatograms obtained
from blank, TAC standard, impurity mixture and test spiked with
impurities mixture solution are shown in Figures 3A, 3B, 3C and 3D,
respectively. The retention times were much more reproducible
on a C8 column and a mixture of TFA and acetonitrile mobile
phase.
UHPLC system has been proved to be a promising tool for
separation of TAC, tautomers and its impurities. Use of small
(1.7 µm) particles of stationary phase enabled optimization of
UHPLC for both peak selectivity and analysis speed. TAC, its
impurities and tautomers were well separated with good peak
shape and resolution. No interfering peaks were observed in blank
and placebo, indicating that signal suppression or enhancement
by the product matrices was negligible. Use of UHPLC resulted
in a reduction in run-time to 25 min, without compromising the
efficiency, compared with a run-time of approximately 45 min on
traditional LC analysis of TAC impurities. LC method will reduce
acetonitrile consumption (at least 80%) without compromising
productivity and performance.
After satisfactory method development, it was subjected to
method validation as per ICH guideline.[26] The method was
validated to demonstrate that it is suitable for its intended
purpose by standard procedure to evaluate adequate validation
characteristics. The result of the system suitability parameter
was found to comply with acceptance criteria: relative standard
deviation of replicate injection is not more than 5.0% and
resolution between Impurity-A and TAC is not less than 2.0
as shown in Table 1. The result of specificity study ascertained
the separation of degradation peaks from TAC peak and the
spectral purity of all exposed samples were found spectrally
pure and data of degradation studies are shown in Table 2.
The %RSD of replicate determination was found to be <5%
in both precision and intermediate precision, which indicates
Figure 3a. Typical Chromatogram of Blank.
110
Figure 3b. Typical Chromatogram of Tacrolimus Standard.
www.drugtestinganalysis.com
c 2010 John Wiley & Sons, Ltd.
Copyright
Drug Test. Analysis 2010, 2, 107–112
Drug Testing
and Analysis
An improved validated ultra high pressure liquid chromatography method
Figure 3c. Typical Chromatogram of Impurities.
Figure 3d. Typical Chromatogram of Test solution spiked with Impurities.
Table 1. Comparison between HPLC and UHPLC method
Parameters
Run time
Resolution between
Impurity-A and
tacrolimus
% RSD of replicate
standard injection
S/N ratio of
Standard
preparation
HPLC
45
minutes
1.0
Table 3. Percentage RSD of impurities in precision study
UHPLC
25
minutes
2.2
2.2
0.6
2.53
22.71
Impurity name
Precision (%RSD)
(n = 6)
Intermediate
precision (%RSD)(n = 6)
3.9
2.7
2.5
2.1
3.2
3.0
2.2
2.7
IMPURITY-A
IMPURITY-B
IMPURITY-C
IMPURITY- D
Table 4. Percentage recovery of impurities at different level
Nominal
% Recovery % Recovery % Recovery % Recovery
concentrations
of IMP-A
of IMP-B
of IMP-C
of IMP-D
Table 2. Results of specificity studies
Stress conditions
Acid hydrolysis
Base hydrolysis
Peroxide degradation
Water hydrolysis
Humidity degradation
Sunlight degradation
Thermal degradation
UV light degradation
Total
degradation
2.44
2.03
0.42
0.87
0.36
0.37
2.33
0.28
Drug Test. Analysis 2010, 2, 107–112
112.9
107.7
100.4
100.6
104.5
93.2
100.0
108.3
87.4
97.2
99.4
113.3
93.1
99.5
103.2
105.5
concentration over the range of about 0.3–6 µg/mL and were
found to be linear (r = 0.999). The data of regression analysis of
the calibration curves are shown in Table 5. The applicability of
the method was verified by the determination of TAC impurities
in Prograf Capsules (Astellas pharma) and stability sample of Inhouse formulation (40 ◦ C/75%RH, 3 month). The impurity content
in both formulations was found to be satisfactory and Table 6
summarizes the results obtained.
Conclusion
Although LC is a versatile technique for the analysis of drugs
in complex matrices, such as biological or pharmaceuticals,
the poor UV absorbency of TAC and its impurities makes the
separation and quantification difficult due to the presence of
interfering substances. A number of analytical approaches have
c 2010 John Wiley & Sons, Ltd.
Copyright
www.drugtestinganalysis.com
111
that the method is precise and the data of precision studies
are shown in Table 3. The results obtained from the recovery
study were found within the range of 85% to 115% (LOQ to
200%), which indicates that the method is accurate and data
for the same are shown in Table 4. Sensitivity of the method
was verified and the method was found to be linear, accurate
and precise at LOQ and the data of LOD and LOQ studies are
given in Tables 4 and 5. The calibration curve of all impurities was
obtained by plotting the peak area of individual impurity versus
LOQ level
50% level
100% level
200% level
Drug Testing
and Analysis
A. Subasranjan, C. Srinivasulu and R. Hemant
Table 5. LOD, LOQ and linearity values of impurities
Parameters
(n=7)
mL−1
LOD µg
LOQ µg mL−1
Calibration range(µg mL−1 )
Calibration Equation
Correlation Coefficient
IMP-A
IMP-B
IMP-C
IMP-D
0.1
0.34
0.34–5.984
y = 7348.9x + (152.17)
0.999
0.1
0.33
0.33–6.06
y = 7739.7x + (−618.86)
0.999
0.1
0.33
0.34–6.114
y = 5877.5x + (−549.92)
0.999
0.1
0.31
0.31–5.992
y = 9010.1x + (−205.42)
0.999
Table 6. Finished products impurity profile data
Product name
Prograf capsules 5.0 mg
Prograf capsules 1.0 mg
Prograf capsules 0.5 mg
In-house capsules 5.0 mg
In-house capsules 1.0 mg
In-house capsules 0.5 mg
% of IMP-A
% of IMP-B
% of IMP-C
% of IMP-D
% of Total Impurity
% of Tautomer-1
% of Tautomer-1I
0.008
0.02
Not Detected
0.03
0.03
0.03
0.02
0.09
0.06
0.11
0.17
0.07
0.04
0.14
0.05
0.25
0.25
0.19
0.20
0.20
0.19
0.33
0.35
0.37
0.37
0.48
0.33
0.76
0.82
0.68
2.02
1.7
1.70
3.07
2.91
2.90
2.50
1.8
1.30
3.09
3.09
2.89
been previously described to determine TAC in biological materials
and pharmaceutical preparation; however, this is the first study
reporting a validated reversed phase method for estimation of
impurity in TAC formulation. The complexities associated with
USP forum reported normal phase chromatographic procedure[25]
are: use of multiple columns, lengthy chromatographic run time
of more than 45 min, non-optimal separation of impurities, and
less sensitivity. These have been addressed by the present UHPLC
method. The simple UHPLC method developed in this study
makes it suitable for separation and estimation of impurities
without interference from excipients and other related substances
present in pharmaceutical matrices. The analytical performance
and the result obtained from analysis of two different formulations
demonstrated that the method is reliable and sufficiently robust.
In conclusion, the high sensitivity, good selectivity, accuracy
and reproducibility of the UHPLC method developed in this
study makes it suitable for quality control analysis of complex
pharmaceutical preparation containing TAC and its impurities. The
reduction of acetonitrile consumption is one of the best solutions
to the current global acetonitrile shortage and will safeguard
against future risk.
Acknowledgements
We wish to express our sincere thanks to the Management of Dr
Reddy’s Laboratories, and to Dr Aniruddha Sherikar and Dr Nilesh.
R. Lad of Dr Reddy’s Laboratories Limited, Hyderabad, India for
their support and encouragement.
References
112
[1] H. Per, N. Thomas, World Intellectual Property Organization, 2006,
WO2005/020994A1.
[2] T. Akashi, T. Nefuji, M. Yoshida, J. Hosoda, J. Pharm. Biomed. Anal.
1996, 14, 339.
[3] Y. Namiki, A. Fujiwara, N. Kihara, S. Koda, T. Yasuda, Chromatographia 1995, 40, 253.
[4] H. Ok, B. H. Arison, R. G. Ball, T. R. Beattie, M. H. Fisher, M. J. Wyvratt,
Tetrahedron lett. 1990, 31, 1035.
www.drugtestinganalysis.com
[5] P. E. Wallemacq, R. Reding, Clin. Chem. 1993, 39, 2219.
[6] V. B. Borhade, H. A. Nair, D. D. Hegde, C. R. Barhate, Drug Dev.
Industrial Pharm. 2009, 35, 440.
[7] A. Capron, J. Lerut, C. Verbaandert, J. Mathys, O. Ciccarelli,
R. Vanbinst, F. Roggen, C. D. Reyck, J. Lemaire, P. E. Wallemacq, Ther.
Drug Monit. 2007, 29, 340.
[8] C. E. Staatz, P. J. Taylor, S. E. Tett, Ther. Drug Monit. 2002, 24, 607.
[9] K. Abu-Elmagd, J. J. Fung, M. Alessiani, A. Jain, R. Venkataramanan,
V. S. Warty, S. Takaya, S. Todo, W. D. Shannon, T. E. Starzl,
Transplantation 1991, 52, 71.
[10] M. Winkler, U. Jost, B. Ringe, G. Gubernatis, K. Wonigeit,
R. Pichlmayr, Transplant Proc. 1991, 23, 3153.
[11] L. Backman, M. Nicar, M. Levy, D. Distant, C. Eisenstein, T. Renard,
R. Goldstein, B. Husberg, T. Gonwa, G. Klintmalm, Transplant Proc.
1994, 26, 1804.
[12] A. J. Beysens, R. M. Wijnen, G. H. Beuman, J. J. Van der Heyden,
G. Kootstra, H. As Van, Transplant Proc. 1991, 23, 2745.
[13] M. Winkler, B. Ringe, J. Baumann, M. Loss, K. Wonigeit, R. Pichlmayr,
Clin. Chem. 1994, 40, 2247.
[14] R. Venkataramanan, L. M. Shaw, L. Sarkozi, R. Mullins, J. Pirsch,
G. MacFarlane, et al. J. Clin. Pharmacol. 2001, 41, 542.
[15] H. Zahir, G. McCaughan, M. Gleeson, R. A. Nand, A. J. McLachlan,
Ther. Drug Monit. 2004, 26, 506.
[16] V. Warty, R. Venkataramanan, P. Zendehrouh, T. McKaveney,
J. Chao, S. Todo, T. Starzl, Transplant Proc. 1991, 23, 954.
[17] W. Piekoszewski, W. J. Jusko, J. Pharm. Sci. 1993, 82, 340.
[18] P. J. Taylor, R. G. Morrist, Ther. Drug Monit. 2003, 25, 259.
[19] A. J. Beysens,
G. H. Beuman,
J. J. van
der
Heijden,
K. E. J. Hoogtanders, O. M. Steijger, H. Lingeman, Chromatographia
1994, 39, 490.
[20] T. Kanji, M. Oh-Hashi, H. Yoshikawa, S. Muranshi, M. Nishiyama,
H. Yoshida, T. Hata, H. Tanaka, J. Chromatogr. 1990, 530, 212.
[21] A. M. Maria, D. S. Laura, T. P. Maria, I. S. Adriana, Journal of AOAC
International. 2006, 89, 1547.
[22] ICH. Impurities in new drug substances 3QA, U.S Food and drug
Administration, IFPMA, Geneva, 2008.
[23] ICH Impurities in new Drug Products 3QB, U.S Food and drug
Administration, IFPMA, Geneva, 2006.
[24] The United States Pharmacopoeia forum, The United States
Pharmacopoeia Convention, Inc. Rockvile, 2008, 35(2), 310 and
312.
[25] N. Lucie, S. Dagmar, S. Petr, J. Separation Sci. 2006, 29, 2433.
[26] ICH. Validation of analytical procedure: Text methodology, U.S. Food
and drug Administration, IFPMA: Geneva, 2005.
c 2010 John Wiley & Sons, Ltd.
Copyright
Drug Test. Analysis 2010, 2, 107–112